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increasing evidence for the role of histone-
modifying enzymes on non-histone substrates, 
including those in the cytoplasm, has been 
emerging in recent years. some chromatin-
modifying proteins, such as the histone methyl 
transferase eZH2, compartmentalize to both 
the nucleus and cytoplasm, whereby eZH2 can 
methylate histones and actin, respectively.1 
Alternatively, the mammalian nuclear mem-
brane disintegrates during mitosis, and the 
structural boundary separating nuclear and 
cytoplasmic proteins breaks down. This allows 
nuclear proteins to diffuse into the cyto-
plasm and potentially catalyze non-nuclear 
substrates. evidence suggests that the Gcn5 
containing histone acetyl transferase complex 
ATAC controls mitotic progression through 
the modification on non-histone targets dur-
ing mitosis.2 And more recently, studies have 
shown that the HiPK2 kinase controls cytoki-
nesis through the phosphorylation of histone 
H2B localized at the midbody, the site of cell 
abscission at the end of mitosis.3 what these 
and other studies suggest is that coordina-
tion and crosstalk between the chromatin and 
cytoskeletal structures is much more inter-
twined than previously appreciated.
in a recent issue of Cell Cycle, we showed 
that the histone ubiquitin ligase RNF8, which 
orchestrates the mammalian DNA damage 
response (DDR) following DNA double-strand 
break (DsB) formation, also controls mitotic 
progression through the ubiquitylation of 
septins in cells4 (Fig. 1). Furthermore, we pro-
vided evidence that this novel role of RNF8 
in mitosis is conserved from budding yeast to 
humans. On the contrary, support for a direct 
role of the yeast RNF8 orthologs Dma1 and 
Dma2 in the DDR or in histone ubiquitylation 
remains lacking. This is partly due to the com-
partmentalization of yeast Dma proteins to 
the cytoplasm,5,6 and partly because Dma-null 
yeast strains lack documented hypersensitivity 
to DNA damaging agents.5 Our preliminary 
studies suggest that Dma1 and Dma2 double-
null yeast strains are hypersensitive to the DNA 
damaging agents hydroxyurea and bleomycin, 
but this has been attributed to a defect in swe1 
protein levels or efficiency of drug uptake 
(cells might be more permeable) and not nec-
essarily to a defect in the DDR per se (Gravel s, 
unpublished). since the phosphorylation of 
the histone variant H2AX and the subsequent 
recruitment of the MDC1 adaptor protein is 
required for mammalian RNF8 localization to 
DsB sitesand since these proteins have con-
served homologs in yeastit is possible that 
the lack of localization of yeast Dma proteins 
to the nucleus might be a critical hindrance 
from them acting on histones. This is especially 
pertinent, because budding yeast cells, unlike 
higher eukaryotic cells, do not disintegrate 
their nuclear membrane during mitosis. in light 
of this, it would be interesting to see whether 
adding a nuclear localization signal to yeast 
Dma proteins could promote their activity on 
nucleosomes following DNA damage.
Taken together, our study suggests that 
RNF8 may have originally arisen to medi-
ate functions in mitosis and was only later 
co-opted to act on histones. Remarkably, in 
both the nucleus and cytoplasm, RNF8 seems 
Figure 1. Cartoon depicting the differential localization and function of RNF8 at nucleosomal and 
cytoskeletal higher order structures during interphase and mitosis, respectively.1162  Cell Cycle  Volume 12 issue 8
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To deal with DNA lesions, cells activate the 
DNA damage response (DDR) network.1 DDR 
activation results in cell cycle delay to allow 
time for DNA repair. Upon excessive damage, 
the cell cycle checkpoint arrest will become 
permanent (a state known as senescence), or 
cells will undergo cell death (apoptosis). A key 
player controlling these cell fate decisions is 
the transcription factor p53. in response to 
genotoxic stress, p53 becomes modified and 
stabilized by different pathways and initially 
induces the expression of genes involved in 
DNA repair and cell cycle arrest. Prolonged p53 
stabilization, however, also induces the expres-
sion of pro-apoptotic genes. This, together 
with the prominent role of p53 in tumor sup-
pression2 highlights the importance of a tight 
control of p53 activity. An exciting new aspect 
of p53 regulation in response to DNA dou-
ble-strand breaks (DsBs), the most toxic DNA 
lesions,1 has now been reported by Moumen 
et al.3
DsBs activate three of the phosphatidylino-
sitol 3-kinase-related kinases (PiKKs), namely 
ataxia telangiectasia mutated (ATM), ataxia 
and Rad3-related (ATR) as well as the DNA-
dependent protein kinase (DNA-PK). These 
kinases phosphorylate a large number of pro-
teins involved in DNA repair, cell cycle check-
points and transcription.1 ATM phosphorylates 
p53 on serine 15 upon DNA damage, thereby 
contributing to p53 activation. ATM also 
phosphorylates HDM2, an ubiquitin e3-ligase 
that regulates p53 protein levels by protea-
somal degradation. Upon DNA damage HDM2 
ubiquitylation of p53 is greatly reduced, lead-
ing to p53 accumulation and p53-dependent 
transcription.2
Heterogeneous nuclear ribonucleopro-
tein  K (hnRNPK) was originally character-
ized as a protein of the ribonucleoprotein 
complex with a strong binding preference 
for poly(C)-sequences in RNA.4 hnRNPK 
has diverse functions, including a role as a 
Figure 1. Pathways through which ATM activates p53-dependent transcription in response to 
ionizing radiation. ATM-targeted phosphorylation sites of hnRNPK identified by Moumen et al.3 are 
indicated.
to target proteins that form poly-octameric 
higher-order structures (Fig. 1). These are the 
histones, which constitute nucleosomes, and 
septins, which form cytoskeletal filaments. 
with their ability to form higher-order chains, 
septins have been described as the “fourth 
component of the cytoskeleton.”7 septin fila-
ments have also been compared with nucleo-
somes, not only because of their structural 
similarity, but also due to their long half-life, 
heavy and reversible post-translational modi-
fications, and their mode of inheritance during 
cell division.8 it is worth noting that our work 
suggests that, in some particular cases, the 
“histone code” might have evolved to mimic 
post-translational modifications occurring in 
cytoskeletal structures rather than the other 
way around. it would be intriguing in the 
future to address such a possibility and ascer-
tain whether RNF168, a ubiquitin e3 ligase 
that works in synergy with RNF8 during the 
DDR, can recognize and mediate subsequent 
septin ubiquitylation events during mitosis. 
More broadly, it will be interesting to deter-
mine whether and how nucleosomal and cyto-
skeletal post-translational modifications are 
coordinated and what the functions for such 
coordination might be.
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Cells are constantly exposed to both endoge-
nous and exogenous stresses that lead directly 
or indirectly to DNA damage. Cell survival 
is dependent on two interrelated processes, 
cell cycle checkpoints and DNA repair; the G1, 
intra-s and G2 checkpoints block cell cycle pro-
gression after DNA damage to provide more 
time for DNA repair. Cell cycle checkpoints 
and DNA repair are integrated through a series 
of signaling networks that involve numer-
ous protein posttranslational modifications   
(e.g., phosphorylation, acetylation, methyla-
tion, ubiquitination) that modulate protein 
stability, catalytic activity and other prop-
erties. Most cancer cells have one or more 
defects in cell cycle checkpoints and often 
defects in some aspect of DNA repair. As a 
consequence, they become addicted to the 
remaining checkpoint and repair mechanisms. 
Tumor therapy often involves treatments that 
cause DNA strand breaks or replication stress. 
The G1, G2 and intra-s checkpoints are acti-
vated in response to DNA strand breaks pri-
marily through the ATM-CHK2 pathway and 
to DNA replication stresses through the ATR-
CHK1 pathway. Thus, disrupting these path-
ways potentially can enhance the therapeutic 
effectiveness of cancer treatments.
in a recent issue of Cell Cycle, Palli 
et al. report1 on the interactions between 
CHK1, PP2A and ATM during the G2 check-
point response to iR-induced DNA dam-
age (Fig.  1). This analysis was motivated by 
studies showing that chemical inhibition of 
CHK1 can enhance chemotherapy for cancer   
(e.g., see ref. 2), and that chemical inhibition 
of CHK1 kinase activity does not fully mimic 
depletion of CHK1 protein. Palli et al. com-
pared and contrasted the effects of CHK1 inhi-
bition in human cell lines by stable depletion 
with shRNA, transient depletion with siRNA 
and chemical inhibition. They found that sta-
ble depletion of CHK1 in 293T cells enhanced 
cellular radiosensitivity in colony-formation 
assays by about 4-fold. As mutation of ATM in 
ataxia telangiectasia enhances radiosensitivity 
about 3-fold, this sensitization by CHK1 deple-
tion is remarkable. Depletion or inhibition of 
CHK1 enhanced phosphorylation at s1981 of 
ATM after iR, but ATM-dependent G2 check-
point function was modestly attenuated. This 
transcriptional co-activator of p53.5 Previous 
work by Moumen et al. showed that hnRNPK 
is stabilized upon ionizing radiation (iR) due 
to a reduction in its HDM2-dependent ubiq-
uitylation, thus enhancing p53-dependent 
transcription after DNA damage.5 To gain 
deeper mechanistic insight into hnRNPK sta-
bilization, Moumen et al. have now shown 
that upon iR treatment, ATM also phosphory-
lates hnRNPK, on 4 serine/threonine residues 
(Fig.  1).3 Phosphorylation by ATM reduced 
hnRNPK ubiquitylation, suggesting that such 
phosphorylation prevents HDM2-dependent 
ubiquitylation and subsequent degradation of 
hnRNPK. The importance of ATM-dependent 
phosphorylation of hnRNPK is illustrated by 
the DNA damage-induced p53-dependent 
transcription of the cell cycle inhibitor p21 
(Fig.  1). Downregulation of hnRNPK with 
RNAi and complementation of its deficiency 
revealed that unlike wild-type hnRNPK, the 
mutant hnRNPK protein that cannot be phos-
phorylated by ATM does not facilitate p21 
expression upon DNA damage.3
Despite the long-term focus on p53 biol-
ogy, many aspects of p53 regulation remain 
unexplained at the molecular level. it remains 
unclear whether ATM-dependent phosphory-
lation of p53 directly disrupts the p53-HDM2 
interaction. Also, while p53 is modified by 
several post-translational modifications upon 
DNA damage, the significance of a poten-
tial crosstalk between these modifications in 
regulation of the abundance and activity of 
p53 remains largely unexplored. For example, 
Aurora A, a mitotic protein kinase, phosphory-
lates both p53 and hnRNPK in the absence 
of DNA damage, leading to a destabilization 
of their interaction. Reduced Aurora A activ-
ity upon DNA damage therefore stabilizes 
the hnRNPK-p53 interaction, thus increasing 
p53 transcriptional activity.6 hnRNPK is also 
sUMOylated upon DNA damage, a modifica-
tion that is required for p53 transcriptional 
activation,7 and it is methylated on several argi-
nine residues, which also seems crucial for p53 
activity.8 Do all of these modifications work in 
an additive manner, or is each of them suffi-
cient for a full p53-dependent cell cycle arrest?
To further complicate things, there are dif-
ferent cellular pools and isoforms of hnRNPK 
performing various functions,9 and it is unclear 
whether ATM phosphorylates all hnRNPK mol-
ecules and which of hnRNPK’s functions are 
affected by this modification. we also do not 
know whether the hnRNPK that is phosphory-
lated by ATM is bound to RNA, or whether such 
phosphorylation affects hnRNPK binding to 
RNA and vice versa. it also remains to be tested 
if hnRNPK becomes phosphorylated on the 
same residues in response to other types of 
genotoxic stress, and whether this is then medi-
ated by different protein kinases such as ATR.
The new study by Moumen et al.3 opens 
the way to answer these questions and help 
better understand the protein network sur-
rounding p53, its physiological roles and mal-
function in cancer cells.
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phenomenology was linked to PP2A, a phos-
phatase that acts on ATM and CHK1, and which 
is regulated by CHK1.3,4 Depletion or inhibition 
of CHK1 reduced (sequestered) nuclear PP2A 
protein levels and enhanced an inhibitory 
phosphorylation of PP2A on Tyr307. The con-
sequence of inhibition of PP2A was increased 
basal and iR-induced phosphorylations on the 
activating s1981 of ATM as well as on s345 
and s296 of the remaining CHK1. Cellular 
growth assays using human mammary epithe-
lial cells with depletion of CHK1 and/or ATM 
showed that combined depletion of CHK1 and 
ATM enhanced radiosensitivity, supporting the 
rationale to use CHK1 inhibitors to increase 
cancer cure rates using adjuvant radio- and 
chemotherapies.2,5
The work by Palii and colleagues highlights 
the cross-talk between different elements of 
the DNA damage response that can produce 
compensatory conditions that mitigate cell 
killing and compromise therapeutic efficacy. 
while crosstalk between the ATM and ATR 
pathways has been known for some time, 
recent proteome-wide analyses of the kinase 
landscape in the DNA damage response impli-
cate the involvement of dozens of kinases and 
highlight how extensive and interlaced the 
pathways in the DNA damage response are 
(reviewed in ref. 6). Although less is known 
about the roles of phosphatases, several in 
addition to the many forms of PP2A, including 
PP1, PP5 and wiP1 (PP2C), are clearly involved 
in the DNA damage response. we note, how-
ever, that inhibition of PP2A with okadaic 
acid prior to iR treatment blocked activation 
of the G2 checkpoint as well as activation of 
ATR, CHK1 and CHK2,7 indicating that the rela-
tionship between ATR, CHK1 and G2 arrest is 
more complex than shown in Figure 1. Other 
posttranslational modifications (e.g., acetyla-
tion, ubiquitination) also play important, if less 
well-studied, roles as well. Furthermore, each 
of the major DNA damage response sensor, 
transducer and effector enzymes serve cellular 
Figure 1. Pathways that can contribute to cancer cell survival. Replication stress activates the 
ATR pathway, leading to activation of CHK1 through phosphorylation of ser345 and ser317; 
ser296 is autophosphorylated and serves as a marker of activated CHK1. ATR also phosphorylates 
ATM on ser1981. CHK1 activity is required for active nuclear PP2A. inhibition or depletion of 
CHK1 decreases nuclear PP2A and increases (through unknown mechanisms) an inhibitory 
phosphorylation of PP2A on Tyr307. inhibition of PP2A results in enhanced phosphorylation of 
CHK1 on ser235 and s296 and ATM on ser1981. Basal signals that activate ATM may come from ATR 
acting at replication forks that are stalled at natural barriers or, after collapse of stalled forks, auto-
activation by DNA double-strand breaks.
functions outside the DNA damage response 
that also must be understood. Thus, a deeper 
understanding of the pathways and mecha-
nisms by which the DNA damage checkpoint 
and repair systems are regulated clearly will be 
important to developing more effective cancer 
therapeutics and therapies.
The Palii et al. study complements several 
recent studies that are attempting to dissect 
these cell survival mechanisms, determine 
how they can be modulated to selectively 
effect death in tumor cells, and how tumor 
cells compensate for the loss of these survival 
mechanisms. For example, a recent report 
in Cell Cycle by McNeely et al.8 described the 
effect of CHK1 inhibition on ATM and DNA-PK 
activity. As oncologists move to targeted anti-
cancer therapies, drug-combination cocktails 
will be needed to squelch compensatory 
events that reduce efficacy.
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Mammalian cyclin e was cloned by groups of 
James Roberts and steven Reed in a screen 
for human cDNAs can complement mutant 
G1 cyclin genes CLN1, CLN2 and CLN3 in yeast 
Sacaromyces cerevisiae.1 The flurry of studies 
that followed this discovery demonstrated 
that in mammalian cells cyclin e is induced 
in late G1 phase, when it activates cyclin-
dependent kinase CDK2, and also CDK1 and 
CDK3. During G1 phase progression, cyclin 
e-CDK2 kinase phosphorylates and inactivates 
the retinoblastoma protein pRB, leading to 
activation of e2F transcription factors. since 
the  cyclin E gene represents one of e2F's 
transcriptional targets, this mechanism cre-
ates a positive feedback loop, which leads to 
full activation of cyclin e-CDK2 kinase. Once 
induced, cyclin e-CDK2 phosphorylates pro-
teins governing cell cycle progression (pRB, 
p27Kip1, e2F5), centrosome duplication (NPM, 
CP110), histone gene transcription (NPAT) and 
others. Cyclin e and cyclin e-CDK2 kinase 
activity is essential for assembly of DNA pre-
replication complexes and for firing of DNA 
replication origins. As the s phase progresses, 
cyclin e becomes phosphorylated by cyclin 
e-CDK2 and by GsK3 and is then targeted 
for proteosomal degradation by the sCFFbw7 
ubiquitin ligase.1
subsequently, groups of Bruno Amati, yue 
Xiong and steve Coats isolated the second 
mammalian e-type cyclin, which was termed 
cyclin e2, while the protein known as “cyclin e” 
was renamed as cyclin e1. The two e-cyclins 
show substantial aminoacid similarity, associ-
ate with the same CDK partners and appear 
to perform similar biological functions.1 Their 
regulation seems to be similar, including tran-
scriptional activation by e2F and protein deg-
radation through sCFFbw7 ubiquitin ligase. Also 
in vivo, the two e-type cyclins seem to per-
form highly overlapping set of functions. Thus, 
genetic ablation of cyclins e1 or e2 resulted in 
no major phenotypes, whereas combined loss 
of both e-cyclins led to an early embryonic 
lethality due to placental abnormalities.2 in 
adult mice, combined ablation of cyclins  e1 
and e2 impairs neuronal synaptic function 
and leads to memory deficits due to a func-
tion of cyclin e in regulating synaptic plas-
ticity.3 Collectively, all these observations 
suggested that cyclins e1 and e2 are function-
ally equivalent.
A recent study from elizabeth Musgrove's 
group4 indicates that this prevailing view may 
need revisions. The authors focused on the 
function of overexpressed cyclin e in breast 
cancer cells. Cyclins e1 and e2 are overex-
pressed in a substantial number of human 
cancers, where they contribute to tumori-
genesis, likely by driving uncontrolled cell 
cycle progression.1 Moreover, overexpression 
of cyclin e1 was shown to result in chro-
mosome instability in in vitro-cultured cells, 
and in vivo in mouse tumors.5,6 while the 
exact molecular mechanism remains to be 
elucidated, this role of cyclin e1 is mediated, 
at least in part, by binding and phosphorylat-
ing the anaphase-promoting complex (APC) 
regulatory subunit, Cdh1.7 This, in turn, inhibits 
APC activity, and results in impaired mitotic 
progression of cyclin e1-overexpressing cells.7 
Unexpectedly, Caldon et al.4 demonstrated 
that cyclin e2, when overexpressed, does 
not interact with Cdh1, does not inhibit APC 
and does not impair mitotic progression. yet 
cyclin e2 overexpression still triggers genomic 
instability, as evidenced by increased fraction 
of abnormal mitoses, as well as the presence 
of chromosomal aberrations, such as chro-
mosome breaks and end-to-end fusions in 
cyclin e2-overexpressing cells. while the mech-
anism through which cyclin e2 causes these 
abnormalities remains unclear, Caldon et al.4 
propose that this effect is mediated through 
inactivation of pRB and pRB-like p107 and 
p130 proteins by hyperactive cyclin e2-CDK2. 
intriguingly, the same group demonstrated 
that the levels of cyclin e2 in cancer cells are 
controlled via a distinct mechanism from that 
operating in normal cells.8 specifically, while in 
non-transformed cells, the levels of cyclins e1 
and e2 are regulated by sCFFbw7, in breast can-
cer cells, depletion of Fbw7 affects the levels of 
cyclin e1 but not e2.8
These finding lead to several questions. 
Are results of Caldon et al.4,8 generalizable 
across different types of human cancers? How 
is the stability of cyclin e2 controlled in cancer 
cells, and how, mechanistically, does cyclin e2 
expression shift from Fbw7-dependent to 
-independent mode? How does cyclin e2 trig-
ger chromosomal instability? Analyses of the 
endogenous protein complexes associated 
with cyclins e1 and e2 in cancer cells may 
help to unravel molecular differences between 
these two related, but apparently distinct, 
proteins.
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